Virtual Library

Start Your Search

Dariusz Dziedzic



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer (ID 393)

      12:30 - 13:00  |  Author(s): Dariusz Dziedzic

      • Abstract
      • Slides

      Background

      Bronchoalveolar lavage fluid (BALF) examination was found to be useful in the evaluation of local immune status in the site of lung cancer development. This procedure may be performed during lung cancer diagnosis and repeated during therapy. It especially concerns the majority of lung cancer cases, which are beyond the possibility of resection at recognition. However, the procedure of BAL in the lung affected by cancer is often complicated. The aim of this study was an analysis of differences in the character of immune response between the lung affected by cancer versus the opposite, ’healthy‘ lung. May BALF from the lung free of tumor serve for the characterization of local immune status?

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      BALF of 36 patients was harvested from the lung affected by cancer and opposite site: the lung without tumor. BALF cells were analyzed by means of the following sets of antibodies anti: the first probe CD4, CD127, CD25, Foxp3, CTLA4, the second probe: CD3, CD16/CD56, CD45, CD19, CD8. For macrophage phenotyping the immunofluorescent method with antibodies anti: CCR7 and CD163 was used. The concentrations of 27 cytokines were analyzed in the duplicate using Bio-Plex Pro Human Cytokine Assay. The next part of the study was performed in other 32 patients by the same method with a panel of antibodies anti: CD3, CD4, CD8, CD127, CD45RA, CD69, CTLA-4, PD-1.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      By the analysis of the BALF profile we found that only the cells and cytokines involved in regulatory pathways showed significant differences between both the ’healthy‘ and the cancerous lung, being elevated in the latter. The proportion of Tregs, CTLA4+Tregs, activated and memory PD-1+ lymphocytes, CCR7lowCD163high macrophages were significantly higher in the lung with cancer than in the healthy lung. On the other hand, the proportion of effectory cells and inflammatory cytokines concentration did not differ between both lungs, which may indicate that they form an integrated immune system and individual homeostasis.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Regulatory mechanisms which are up-regulated in the tumourbearing lung affect BALF profile in the lung with cancer, while the examination of BALF from the “healthy” lung may serve for the evaluation of individual basic profile of the anti-cancer response.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      J. Domagala-Kulawik: Travel grant, consultant: BMS, MSD. All other authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      36P - Can a BALF profile distinguish hot vs cold lung tumors? (ID 389)

      12:30 - 13:00  |  Author(s): Dariusz Dziedzic

      • Abstract
      • Slides

      Background

      Immunotherapy brings evident benefits to lung cancer patients. However, the answer to this treatment is highly individualized and seems to be better in ‘hot’ tumors than in ’cold’ ones. The vast majority of lung cancers are in their advanced stages at recognition, therefore the access to large fragments of tumor tissue and tumor environment is limited. The results of our previous studies showed the usefulness of bronchoalveolar lavage fluid (BALF) examination in the evaluation of immune status in a lung tumor site. The aim of this study was to assess if BALF may reflect the signs of ‘hot’ vs. ‘cold’ tumors.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      36 lung cancer patients were investigated. The number of lymphocytes and the proportion of following lymphocyte subtypes were analysed by flow cytometry: T, B, T helper, T cytotoxic, NK cells, CD25+Th cells, T regulatory cells, CTLA4+Tregs. The concentration of IFNγ, TNFα, VEGF, TGFβ, IL-2, IL-10 was measured by Bio-Plex Pro Human Cytokine Assay. We defined ’hot‘ tumors by the presence of cell proportion or cytokine concentration above the median value and ’cold‘ tumors where these markers were lower than the median value.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      There were 36% of BALF samples with more than 2 parameters below the median values, which may reflect ’cold‘ tumors. The indications of immune response (more than 7, e.g. 50%) were elevated in 53% samples. The majority of ’hot‘ tumors were in the type of adenocarcinoma or NOS, but without any relation to the EGFR mutations nor ALK alterations. No relation between the intensity of immune response in the BALF and the clinical stage of cancer was observed.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      BALF examination may help in distinguishing ’hot‘ and ’cold‘ lung cancer and may be useful in the characterization of local immune status before treatment. By extrapolating the results of this study we could recommend BALF as a source of useful biomarkers before immunotherapy.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      J. Domagala-Kulawik: Travel grants, consultations: BMS, MSD. All other authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.